Literature DB >> 16575348

Octreotide efficacy in the treatment of chylothoraces following cardiac surgery in infants and children.

Maple T Landvoigt1, Charles J Mullett.   

Abstract

OBJECTIVE: To examine the efficacy of octreotide in resolving chylothoraces in infants and children following cardiac surgery.
DESIGN: Retrospective chart review.
SETTING: Pediatric intensive care unit of a tertiary care center. PATIENTS: All children who received octreotide for the treatment of chylothoraces following surgery for congenital heart disease over a 30-month period between 2001-2004.
INTERVENTIONS: Octreotide infusion.
MEASUREMENTS AND MAIN RESULTS: Eight courses of octreotide treatment were identified in seven patients who met our inclusion criteria. The median duration of therapy was 5 days, and dosing ranged from 1 to 4 microg/kg/hr. Treatment did not result in an overall decrease in average chest tube output after 3 days of therapy. However, in two patients (29%) the chylothoraces ultimately resolved during the octreotide infusion. Treatment was well tolerated, and no serious side effects were noted.
CONCLUSION: In contrast to previously published reports, we find octreotide therapy for postoperative chylothoraces to be successful in only a minority of cases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16575348     DOI: 10.1097/01.PCC.0000216683.00110.0E

Source DB:  PubMed          Journal:  Pediatr Crit Care Med        ISSN: 1529-7535            Impact factor:   3.624


  5 in total

1.  Chylothorax after pediatric cardiac surgery complicates short-term but not long-term outcomes-a propensity matched analysis.

Authors:  Nikoletta R Czobor; György Roth; Zsolt Prodán; Daniel J Lex; Erzsébet Sápi; László Ablonczy; Mihály Gergely; Edgar A Székely; János Gál; Andrea Székely
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

2.  Evaluating the Use of Octreotide for Acquired Chylothorax in Pediatric Critically Ill Patients Following Cardiac Surgery.

Authors:  Annie Bui; Courtney J Long; Robin L Breitzka; Joshua S Wolovits
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Sep-Oct

Review 3.  Octreotide for Acquired Chylothorax in Pediatric Patients Post-Cardiothoracic Surgery for Congenital Heart Disease: A Systematic Review.

Authors:  A C Jenkinson; J McGuinness; T Prendiville
Journal:  Pediatr Cardiol       Date:  2022-10-18       Impact factor: 1.838

4.  Postoperative chylothorax development is associated with increased incidence and risk profile for central venous thromboses.

Authors:  M A McCulloch; M R Conaway; J A Haizlip; M L Buck; V E Bovbjerg; T R Hoke
Journal:  Pediatr Cardiol       Date:  2007-11-21       Impact factor: 1.655

5.  Safety of octreotide in hospitalized infants.

Authors:  Daniela Testoni; Christoph P Hornik; Megan L Neely; Qinghong Yang; Ann W McMahon; Reese H Clark; P Brian Smith
Journal:  Early Hum Dev       Date:  2015-05-15       Impact factor: 2.699

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.